Abstract
A missense somatic mutation in JAK2 gene (JAK2 V617F) has recently been reported in chronic myeloproliferative disorders, including polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia, strongly suggesting its role in the pathogenesis of myeloid disorders. As activation of JAK2 signaling is occurred in other malignancies as well, we have analysed 558 tissues from common human cancers, including colon, breast and lung carcinomas, and 143 acute adulthood leukemias by polymerase chain reaction – single strand conformation polymorphism analysis. We found three JAK2 mutations in the 113 acute myelogenous leukemias (AMLs) (2.7%), but none in other cancers. The mutations consisted of two V617F mutations and one K607N mutation. None of the AML patients with the JAK2 V617F mutation had a history of previous hematologic disorders. This is the first report on the JAK2 gene mutation in AML, and the data indicated that the JAK2 gene mutation may not only contribute to the development of chronic myeloid disorders, but also to some AMLs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L . (1976). N Engl J Med 295: 913–916.
Arteaga CL, Moulder SL, Yakes FM . (2002). Semin Oncol 29: 4–10.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. (2005). Lancet 365: 1054–1061.
Dameshek W . (1951). Blood 6: 372–375.
Diez-Martin JL, Graham DL, Petitt RM, Dewald GW . (1991). Mayo Clin Proc 66: 287–299.
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. (2001). N Engl J Med 344: 1038–1042.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. (2005). Nature 434: 1144–1148.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. (2005). N Engl J Med 352: 1779–1790.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. (2005). Cancer Cell 7: 387–397.
Pallis M, Seedhouse C, Grundy M, Russell N . (2003). Leuk Res 27: 803–805.
Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN et al. (2002). Blood 99: 4094–4099.
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. (2005). Blood [Epub ahead of print].
Swolin B, Weinfeld A, Westin J . (1988). Blood 72: 386–395.
Verma A, Kambhampati S, Parmar S, Platanias LC . (2003). Cancer Metastasis Rev 22: 423–434.
Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ et al. (2002). Cancer Res 62: 5749–5754.
Acknowledgements
This work was supported by the Korea Science & Engineering Foundation (KOSEF) through the Cell Death Disease Research Center at The Catholic University of Korea (R13-2002-005-01004-0).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, J., Kim, Y., Soung, Y. et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25, 1434–1436 (2006). https://doi.org/10.1038/sj.onc.1209163
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209163
Keywords
This article is cited by
-
Thrombocytosis in children and adolescents—classification, diagnostic approach, and clinical management
Annals of Hematology (2021)
-
Molecular therapy for acute myeloid leukaemia
Nature Reviews Clinical Oncology (2016)
-
JAK inhibitors suppress t(8;21) fusion protein-induced leukemia
Leukemia (2013)
-
BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease
Molecular Cytogenetics (2012)
-
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Nature Reviews Drug Discovery (2011)
